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Abstract
Background: Analytical imaging by secondary ion mass spectrometry (SIMS) provides images
representative of the distribution of a specific ion within a sample surface. For the last fifteen years,
concerted collaborative research to design a new ion microprobe with high technical standards in
both mass and lateral resolution as well as in sensitivity has led to the CAMECA NanoSims 50,
recently introduced onto the market. This instrument has decisive capabilities, which allow
biological applications of SIMS microscopy at a level previously inaccessible. Its potential is
illustrated here by the demonstration of the specific affinity of a melanoma marker for melanin. This
finding is of great importance for the diagnosis and/or treatment of malignant melanoma, a tumour
whose worldwide incidence is continuously growing.
Methods: The characteristics of the instrument are briefly described and an example of application
is given. This example deals with the intracellular localization of an iodo-benzamide used as a
diagnostic tool for the scintigraphic detection of melanic cells (e.g. metastasis of malignant
melanoma). B16 melanoma cells were injected intravenously to C57BL6/J1/co mice. Multiple B16
melanoma colonies developed in the lungs of treated animals within three weeks. Iodobenzamide
was injected intravenously in tumour bearing mice six hours before sacrifice. Small pieces of lung
were prepared for SIMS analysis.
Results: Mouse lung B16 melanoma colonies were observed with high lateral resolution. Cyanide
ions gave "histological" images of the cell, representative of the distribution of C and N containing
molecules (e.g. proteins, nucleic acids, melanin, etc.) while phosphorus ions are mainly produced
by nucleic acids. Iodine was detected only in melanosomes, confirming the specific affinity of the
drug for melanin. No drug was found in normal lung tissue.
Conclusion: This study demonstrates the potential of SIMS microscopy, which allows the study
of ultra structural distribution of a drug within a cell. On the basis of our observations, drug
internalization via membrane sigma receptors can be excluded.
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Progress in cellular imaging allows access not only to
qualitative aspects of living structures but also to quanti-
tative data. These data are of considerable interest, espe-
cially in pharmaco-toxicology, to understand the
mechanisms by which drugs interact with physiological
processes. Such analytical methods have, for a long time,
been restricted to fluorescence measurements, either
directly or after immuno-conjugation, thus severely limit-
ing the development of such applications. In the last few
decades, new techniques have appeared, including X-ray
fluorescence, electron energy loss spectroscopy, and sec-
ondary ion mass spectroscopy (SIMS).
Initially introduced 40 years ago [1], SIMS imaging has
found its main uses in microanalysis of mineral samples,
e.g. in geology, metallurgy, and semiconductor sciences.
Application of this "ion microscopy" to life sciences was
attempted by Pierre Galle more than 30 years ago [2].
However, the complex nature of biological samples and
the poor performance of the first instruments limited its
use to various "histological" studies, mainly in nuclear
medicine and radionuclide toxicology.
SIMS imaging is based on the sputtering of secondary par-
ticles under the impact of high-energy primary ions. Upon
the impact of these primary ions, most chemical bonds
are broken and atoms or polyatomic fragments are ejected
from the most superficial atomic layers of the specimen
(1–2 nm), either as neutral or charged particles (ions).
Ions can be selected by a mass spectrometer on the basis
of their mass to charge ratio (m/z), while maintaining the
topological information of their origin intact thus leading
to images representative of the spatial distribution of a
specific ion within the sample surface. This imaging tech-
nique has been recently reviewed on the basis of past
experiments using standard technology [3-5]. For the last
fifteen years, concerted collaborative research to design a
new ion microprobe with high technical standards in
both mass and lateral resolutions as well as in sensitivity
has led to the CAMECA NanoSims 50 [6,7] recently intro-
duced on the market (Cameca S.A., Courbevoie, France,
http://www.cameca.fr). A highly simplified diagram of
this new instrument is given in figure 1. This machine has
decisive capabilities, which can be used for biological
applications of SIMS microscopy at a level previously
inaccessible. The main characteristics of this new ion
microscope are:
i) high lateral resolution (≤50 nm with caesium primary
ions and ≤150 nm with oxygen primary ions),
ii) capability to measure up to 5 masses (ions) in parallel,
coming from the same micro volume (ensuring perfect
isotopic ratio from the same small volume or perfect
image superimposition)
iii) very good transmission, e.g. high sensitivity, even at
high mass resolution (60% at M/∆M = 5000).
The main advantage of this technology is the ability to
make direct observation of the distribution of any ele-
ment (and all isotopes) occurring at the surface of a sam-
ple, without any specific labelling with a fluorescent or
radioactive probe.
In the present paper, we describe an example of applica-
tion of this new ion microprobe to a problem in cancer
pharmacology, the targeting of melanin for the diagnosis
and/or the treatment of malignant melanoma.
The worldwide incidence of malignant melanoma is con-
tinuously increasing [8,9] and it is now evident that diag-
nosis at an early stage is the most effective way to limit
mortality. The most common tool to determine the extent
of the disease is whole body scintigraphic exploration
and, for this purpose, two classes of compounds are cur-
rently under investigation, 18F-fluorodeoxyglugose
(18FdG), a non-specific tumoral tracer [10], and 125I-iodo-
benzamides (125I-BZA), a series of specific imaging agents
for melanoma [11-16]. These latter molecules can also be
used as internal radio therapeutic agents after labelling
with the β-emitter 131I. Whilst the affinity of these iodo-
benzamides for melanoma tissue has been the subject of
numerous studies, their tissue and cell distribution as well
as their uptake mechanism remain controversial. A recent
SIMS microscopy study of tissues that were either neoplas-
tic or from normal pigmented skin, of C57Bl6/J1 mice inoc-
culated with malignant murine B16 melanocytes has
shown the intracytoplasmic localization of the drug in
both types of cell. However, lateral resolution of the
instrument was too low to identify any characteristic
intra-cellular structure such as melanosomes, and so the
results were not fully conclusive [17]. The results pre-
sented here demonstrate unambiguously the specific
affinity of the studied iodobenzamide for melanin pig-
ments present within melanosomes.
Methods
B16 murine melanoma cells were cultivated in minimal
essential medium (MEM) supplemented with 10% foetal
calf serum (FCS) and standard antibiotics. For transplan-
tation, cells were trypsinized and washed with buffered
saline (PBS) containing 5% FCS. Then, cells were resus-
pended in PBS (1.5 × 10-6 cells/mL) and 0.2 mL of the sus-
pension was injected intravenously to C57BL6/J1/co mice
(Iffa Credo, France). Multiple B16 melanoma colonies
developed in the lungs within three weeks. All animal usePage 2 of 7
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guidelines for animal welfare.
N-2-Diethylaminoethyl-4-iodobenzamide (127I-BZA) was
injected intravenously in tumour bearing mice (0.9 mg/
0.2 mL/mouse; 2.6 µmole) 6 hours before sacrifice. Lungs
were removed and small pieces of tissue were fixed by
slam freezing. Samples were dehydrated by lyophilization
at -110°C before embedding in spurr® resin at low temper-
ature. Serial sections of 0.4 µm were deposited on stain-
less steel disks for SIMS analysis or on glass slides for light
microscopy.
SIMS observations were carried out on a Nanosims 50®
micro beam analyzer (CAMECA, Courbevoie, France)
using a Cs+ primary source (15 KeV). The probe was 80
nm in diameter, with an intensity of 1.5 pA. Distribution
of negative ions: CN- (m = 27), P- (m = 31), and I- (m =
127) was recorded as a matrix of 256 × 256 image points.
Mass resolution (M/∆M) was above 6000 and mass cali-
bration was achieved using standard references. Lateral
resolution was in the range 80–100 nm.
Results
As shown on an optical image (Fig. 2), B16 colonies
appear as clusters of large cells, which can be easily
Synopsis of the instrumentFigure 1
Synopsis of the instrument. Highly simplified synopsis of the NanoSims50® instrument showing the beams of primary (red) 
and secondary (blue) ions and the five detectors along the focal plane of the magnet.Page 3 of 7
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grains can be seen as small black spots, which are charac-
teristic of all pigmented melanoma cells. Sims images cen-
tred on one B16 colony are given in figures 3 and 4, while
figure 5 is representative of normal lung tissue.
CN- ions correspond to nitrogen distribution, mainly
from proteins and melanin, while phosphorus ions are
essentially concentrated in the nucleus and are mostly
emitted by nucleic acids. However, as expected, phospho-
rus is also apparent everywhere in the cell, whilst iodide
ions only arise from BZA or/and its metabolites.
CN- distribution gives an image very similar to that
obtained using light microscopy. We can observe some
small grains (150–250 nm in diameter) as well as a cluster
of such grains (Figs. 3A and 3D) with a very high signal
intensity. These hyper signal areas are totally free of
phosphorus signal (Figs. 3B and 3E), as expected for mel-
anin, which is a polymeric structure containing no phos-
phorus. A perfect correlation is found between these
structures and the iodine signal (Figs. 3C and 3F), thus
indicating a specific colocalization of the drug with mela-
nin. The cluster, which can be considered as a melano-
some, and most melanin grains, are intracytoplasmic and
no iodine signal can be observed at the cytoplasmic mem-
brane locus. Therefore, our results invalidate, at least for
N-2-diethylaminoethyl-4-iodobenzamide, the hypothesis
of John and colleagues implicating a specific binding of
benzamides to membrane sigma receptors [18,19]. The
same observations are true for figure 4, however, here the
melanin grains are rare. Interestingly, in the CN- image
(Fig. 4A), the central cell of the picture does not show any
structured nucleus but rather a "patchwork" of high signal
areas, which appear as very intense signals in the phos-
phorus image (Fig. 4B). This is consistent with a metapha-
sic cell in which the chromatin is already condensed into
chromosomes. Normal lung tissue, shown in figure 5, did
not elicit any significant iodine signal, thus indicating the
high specificity of the drug for the melanin of pigmented
cells.
Conclusions
Iodobenzamide has a high affinity for melanin and, when
labelled with 125I, this molecule appears as a highly spe-
cific tool for the diagnosis of micro metastasis from pig-
mented malignant melanoma. Its use as an internal
radionuclide therapeutic agent bearing the β-emitter 131I
is currently under investigation. However, the therapeutic
protocol should be established with great care, since BZA
can also bind to normal pigmented cells, i.e. in the retina
or in the skin, which can be destroyed as along with the
targeted malignant cells.
This study demonstrates the high potential of SIMS micro-
scopy, which now allows the study of ultra structural dis-
tribution of a drug within a cell. The high lateral
resolution, as well as the high sensitivity, make possible
the observation of organelles as small as melanosomes.
This new technology merits further applications to the life
sciences as a major advance to an "old".
B16 melanoma coloniesFigur  2
B16 melanoma colonies. Histological sections (0.4 µm) of mouse lung bearing B16 melanoma colonies (×200, left and ×400, 
right). Melanoma cells appear as large and dense structures with many dark grains of melanin.Page 4 of 7
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Secondary negative ion images of B16 melanoma cells from a mouse lung colony. A & D: CN- ions (m = 26) – B & 
E: P- ions (m = 31) – C & F: I- ions (m = 127). D-F are enlargements of the top left part of A-C. In the bottom row, the use of 
specific colours for each type of ion (red for CN, green for P and blue for I) allows the superimposition of the various images 
leading to colour variations resulting from the co-localization of the observed ions. Thus, yellow coloration in CN+P corre-
sponds to the co-localisation of CN- and P- ions while a co-localization of the iodine with very intense spots of the CN image 
(purple coloration in CN+I) can be seen. This iodine signal corresponds to the melanin, which appears in red on the CN+P 
image and in blue on the P+I image, since melanin does not contain any phosphorus. The strongest signals in the phosphorus 
image are attributed to cell nucleus, namely to active chromatin and nucleoli. Observed fields A-C: 20 µm × 20 µm, D-F and 
superimpositions: 10 µm × 10 µm.Page 5 of 7
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SIMS images of B16 melanoma cells from a mouse lung colony. A: CN- ions (m = 26) B: P- ions (m=31) – C: I- ions (m 
= 127), field 20 × 20 µm. As shown in figure 3, false colors allow the superimposition of the various ions. Iodine is strictly co-
localized with melanin, which is essentially intracytoplasmic. The central cell is metaphasic and chromosomes can be seen in the 
pictures.
SIMS images of normal mouse lung tissueFigure 5
SIMS images of normal mouse lung tissue. A: CN- ions (m = 26) B: P- ions (m = 31) – C: I- ions (m = 127), field 20 × 20 
µm. The iodine image does not show any significant signal.Page 6 of 7
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